Vertex Pharmaceuticals Incorporated

After the explosive increase in the obesity market size led by GLP-1 agonist therapies in the last few years, the natural question is: what will biopharma’s next big growth markets be? Scrip has int

Not even two months into the new year and some of the expected biggest-earning new drugs of 2025 have already been approved. An updated analysis conducted by Scrip and Evaluate Pharma of drugs expec

The past year yielded a downward trend across the board for dealmaking in the biopharmaceutical sector, regardless of which metric one looks at. In the area of mergers and acquisitions, deal volume, t

The US Food and Drug Administration’s approval of two new vaccines places the spotlight on what would normally be a routine next step on the road to market, the US Center for Disease Control and Preve